Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brooks LaboratoriesBOM:533543 -1.82%55 Days Payable is 84.04 as of Mar. 2026, which is 46% below its 10-year median of 155.09. GuruFocus rates BOM:533543 with a GF Score™ of 55/100 and a GF Value™ of ₹118.09 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 925 Drug Manufacturers companies, Brooks Laboratories ranks worse than 51.78% on this metric.
The historical rank and industry rank for Brooks Laboratories's Days Payable or its related term are showing as below:
BOM:533543'
s Days Payable Range Over the Past 10 Years
Min: 87.62 Med: 155.09 Max: 215.98
Current: 87.62
During the past 13 years, Brooks Laboratories's highest Days Payable was 215.98. The lowest was 87.62. And the median was 155.09.
BOM:533543's Days Payable is ranked worse than 51.78% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:533543: 87.62
Brooks Laboratories's Days Payable
increased
from Mar. 2025 (78.63) to Mar. 2026 (84.04).
It may suggest that Brooks Laboratoriesdelayed paying its suppliers.
Brooks Laboratories Days Payable Related Terms
Brooks Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Brooks Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brooks Laboratories (BOM:533543) has a Days Payable of 84.04 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Brooks Laboratories and its competitors. This is 46% below median its historical median of 155.09. Over the past decade, Brooks Laboratories' Days Payable has ranged from 87.62 to 215.98. According to the industry distribution chart, Brooks Laboratories ranks #479 out of 925 companies in the Drug Manufacturers industry, placing it in the top 51.8%.
Is Brooks Laboratories' Days Payable too high?
Brooks Laboratories' current Days Payable of 84.04 is 46% below median its 10-year median of 155.09. Over the past 10 years, this metric has ranged from a low of 87.62 to a high of 215.98. The Drug Manufacturers industry median Days Payable is 90.38. Brooks Laboratories' value of 84.04 is 7% below this industry median. Based on the distribution chart, Brooks Laboratories ranks #479 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Brooks Laboratories has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #479 out of 925 companies for Days Payable. This places Brooks Laboratories in the lower half of its industry. The industry median Days Payable is 90.38. Brooks Laboratories' value of 84.04 is 7% below this benchmark. Historically, Brooks Laboratories' own Days Payable has ranged from 87.62 to 215.98 over the past decade. While the company's 10-year median is 155.09 vs. the industry median of 90.38, Brooks Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brooks Laboratories's current Days Payable of 84.04 is 7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current Days Payable is 84.04, which is 46% below median its own 10-year median of 155.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹118.09, compared to a current price of ₹66.76 — trading 43.5% below its estimated fair value. The current Days Payable is 84.04, which is 46% below median its 10-year median of 155.09 and 7% below the Drug Manufacturers industry median of 90.38. Brooks Laboratories' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Days Payable is 84.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹66.76 is trading 43.5% below its estimated GF Value™ of ₹118.09.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
Days Payable: 84.04 (46% below median its 10-year median of 155.09)
GF Value™: ₹118.09 vs. price of ₹66.76 (43.5% below fair value)
Industry Position: 7% below the Drug Manufacturers median (#479 of 925)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
55GF Score
Get the complete analysis for BOM:533543
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
